Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SFDA Approval Granted to SIBS Swine Flu Vaccine

publication date: Sep 16, 2009

The Shanghai Institute of Biological Sciences (SIBS) has won SFDA approval to produce its single-dose vaccine for H1N1 swine flu. The Institute expects to produce 3 million doses of the vaccine by October 1 and 10 million doses by year end. SIBS is the third China entity to be given approval for a swine flu vaccine; the other two are Sinovac Biotech (北京科兴生物制品有限公司) and Hualan Biological Engineering Inc. More details...

Stock Symbol: (NYSE Amex: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital